AbbVie, Besins must pay $448 million in FTC AndroGel case, judge rules
AbbVie and Besins Healthcare violated antitrust law by filing sham patent litigation to delay the availability of generic AndroGel, a Philadelphia federal judge ruled Friday, ordering the companies to pay $448...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content